by TractManager | Mar 5, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Rebyota (fecal microbiota, live-jslm) for prevention of recurrent Clostridioides difficile infection (rCDI).
by TractManager | Mar 5, 2024 | Emerging Technology Report
Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) is an investigational oral small molecule sigma-1 receptor agonist for treatment of early Alzheimer disease.
by TractManager | Feb 27, 2024 | Emerging Technology Report
Lifileucel (Amtagvi; Iovance Biotherapeutics Inc.) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation...
by TractManager | Feb 26, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the currently available design of the ApiFix (ApiFix Ltd.) minimally invasive deformity correction system for...
by TractManager | Feb 22, 2024 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Kerecis Omega3 Wound (Kerecis) fish skin grafts for treatment of burns.
Recent Comments